Format

Send to

Choose Destination
Nat Rev Rheumatol. 2017 Oct;13(10):621-630. doi: 10.1038/nrrheum.2017.146. Epub 2017 Sep 14.

Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?

Author information

1
Institute of Genetics, Department of Biology, University of Erlangen-Nuremberg, Erwin-Rommel-Str. 3, 91058 Erlangen, Germany.
2
Medical Immunology Campus Erlangen, Department of Biology, University of Erlangen-Nuremberg, Staudtstr. 5, 91058 Erlangen, Germany.

Abstract

A loss of humoral tolerance is a hallmark of many autoimmune diseases and the detection of self-reactive antibodies (autoantibodies) of the immunoglobulin G (IgG) isotype is widely used as a biomarker and diagnostic tool. However, autoantibodies might also be present in individuals without autoimmune disease, thus limiting their usefulness as a sole indicator of disease development. Moreover, while clear evidence exists of the pathogenic effects of autoantibodies in mouse model systems, the contribution of autoantibodies to the pathology of many autoimmune diseases has yet to be established. In this Review, the authors discuss the changes in total serum IgG and autoantibody glycosylation that occur during autoimmune disease and how these changes might help to predict disease development in the future. Furthermore, current knowledge of the signals regulating antibody glycosylation and how individual antibody glycoforms could be used to optimize current treatment approaches will be discussed.

PMID:
28905852
DOI:
10.1038/nrrheum.2017.146
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center